Subscribe
Subscribe

Europe’s Life Sciences Paradox: Strong Science, Weak Scale?

Europe has long positioned itself as a global leader in life sciences. With world-class research institutions and a steady pipeline of scientific breakthroughs, that claim is well founded. But at the heart of the ecosystem, there is a growing disconnect. Is Europe equipped to build and retain globally competitive companies, or is it just a generator of innovation for others to scale?

Breaking the Cycle of Pain: Biodol’s Solution for the Opioid Crisis

Biodol Therapeutics is aiming to ease the burden of chronic pain for millions of patients around the globe. The company is developing a unique new drug with a dual function: a non-opioid standalone treatment for neuropathic pain or migraine, but also a combination therapy with opioids. By reversing opioid tolerance, Biodol’s compound eliminates the need for higher doses, making these powerful drugs safer and more effective at alleviating suffering.

Bacteria as Plant Fertilizers: How Soil Microbes Can Help Plants Grow During Drought

Farmers rely heavily on chemical fertilizers to boost crop yields, but this approach comes at a cost to soil quality, biodiversity, and plant fertility. Soil microbes may provide greener alternatives to help plants grow better under tough conditions like drought by triggering faster growth and earlier flowering. The intended result? Improved crop yields when water is scarce.

From Copycat to Top Dog: China is Becoming a Biopharma Powerhouse

With the rapid rise of Chinese biopharma, this ‘new kid on the block’ has gone from baby to behemoth on the world stage. This powerhouse of innovation and industry is now turning heads in both the US and Europe, having transformed from copycat to top dog in the space of just a few years. How has China done it, and what can Europe do in response?

Stop Being a Pest About It: How AI Can Help Agriculture

Insect pests are a major cause of quality and economic losses in agriculture. Due to policy constraints that aim for a greener future, the use of general pesticides is being phased out, and a push towards species-specific pesticides and biological control methods is being promoted. But these methods require the pest species to first be identified, which is costly. AI could help speed up this process, thus reducing costs and helping us push towards a greener tomorrow.

R&D Real Estate: A Cornerstone of European Innovation

The most visible — yet often overlooked — parts of an innovative ecosystem are the buildings that house research and development activities. Far more than just office space, these physical foundations facilitate the translation of lofty ideas into tangible solutions for society. Kadans Science Partner is one of Europe’s foremost providers of this specialized infrastructure, with a unique community-minded model.

Health Innovation Funding: Spearhead Clusters Lead the Way in Flanders

BioVox spoke with Sara Van Overmeire and Annie Renders of Flanders Innovation & Entrepreneurship (VLAIO) about the origin and role of spearhead clusters. VLAIO is the Flemish government’s point of contact for all entrepreneurs in Flanders. It relies on Biovia and other spearhead clusters to bring companies together and support them in setting up innovative projects.

MeSH Counter: A Tool to Track Biomedical Research Trends

Venture investing in early-stage companies hinges on spotting transformative technologies before they become hyped. To support this, we built the MeSH Counter: an R-based tool that tracks monthly frequencies of specific terms in PubMed, allowing us to visualize trends in the life sciences. Publication trends are not the same as investment signals, yet the MeSH Counter can help efficiently map the research landscape, so investors can prioritize deeper, human-led diligence.

Bioprinting Living Tissues with BIO INX

Belgian startup BIO INX develops bioinks to 3D print cells into living tissues and organ-on-chip technologies. The company is working with academic and industry partners to develop products ranging from artificial corneas to cartilage. The aim: translate academic ideas into to real-world applications with tangible patient impact.

Co-Creation in Agrifood and Bio-Based Innovation: Accelerating Trust and Impact

As a sector, agrifood biotech has enormous potential to improve the sustainability, resilience, and productivity of our food systems. Yet many promising innovations still fail to reach the market, often because they are not sufficiently aligned with real-world needs or adoption barriers. The B-Trust project aims to involve end-users from the start, to help make agrifood R&D more relevant, equitable, and impactful.

Dengue: A Virus Without Borders

We are all familiar with global viruses: The flu shows up every year across the world, and not long ago we collectively experienced the SARS-CoV-2 pandemic. Now, a neglected tropical disease is joining this club of viruses without borders. Dengue — also known as break-bone fever — is currently one of the world’s fastest spreading viral diseases, with more than half of the global population already at risk.

MDR and IVDR Revisions Bode Well for European Medtech Innovation

In December 2025, the European Commission unveiled proposed revisions to the EU’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). The changes aim to accelerate the path to market for medtech and digital health companies by making the rulebook easier to navigate without lowering the bar on patient safety. Innovators have greeted the announcement with cautious optimism.

Mind Over Money: US vs. European Investment Psychology in Biotech

Early-stage biotech investing has always demanded a high tolerance for uncertainty, and an uncanny ability to predict which fledgling technologies will one day reshape health. But one silent force shapes investment outcomes more often than we admit: psychology. At the intersection of capital and culture, we find a compelling and underexplored story — the differences between investors in the US and Europe, and how these contrasts play out in biotech.

To PhD or Not to PhD: A Growing Question in the Life Sciences

An increasing number of PhD students are concerned about their career prospects. Currently, only around 5-10% of PhD graduates remain in academia — the vast majority have to navigate an unfamiliar job market, where industry demand for their highly educated profiles appears to be in decline. Is a PhD still the best route to professional success? And what can students do to prepare themselves?

The Portfolio Career: A New Prescription for Medicine’s Future

For many years, medicine has offered doctors a clear and stable path in clinical practice. But today, rising burnout, evolving patient needs, and rapid technological change are exposing the limits of that one-track career. Increasingly, physicians are redefining their roles, blending clinical work with research, policy, entrepreneurship, and more. These emerging portfolio careers may hold the key to personal fulfillment and a more resilient workforce, in medicine and beyond.